Submissions for variant NM_000527.5(LDLR):c.974G>A (p.Cys325Tyr)

dbSNP: rs879254746

Total submissions: 10

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel	RCV000238286	SCV002506391	likely pathogenic	Hypercholesterolemia, familial, 1	2022-02-09	reviewed by expert panel	curation	The NM_000527.5 (LDLR): c. 974G>A (p.Cys325Tyr) variant is classified as Likely Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PM2, PM1, PS4_Moderate, PP3, PP4, PS3_Supporting,) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PM2 Met: This variant is absent in gnomAD (gnomAD v2.1.1). PP3 Met: REVEL = 0.977, which is above the threshold of 0.75. PM1 Met: The variant meets PM2, and alters Cys325, which is located in EGF-like 1 domain and is one of 60 highly conserved cysteine residues. PS3_Supporting Met: FACS assay using heterozygous patients’ lymphocytes (level 3 functional assay) showed 50-60% LDLR activity compared to wild type, from one research lab (CEINGE-Biotecnologie Avanzate, Napoli, Italy, PMID21865347). PP4 Met: This variant meets PM2 and is identified >1 index cases who met clinical criteria for FH after alternative causes for high cholesterol were excluded. PS4_Moderate Met: Variant meets PM2 and is identified in 8 unrelated index cases. Five of the index cases fulfil DLCN criteria for FH from 5 different laboratories (1 case from Mayo Clinic Atherosclerosis and Lipid genomics Laboratory, LabID500068; 1 case from University of Genova-University of Modena and Reggio Emilia, Italy, PMID32977124; 1 case from Lipid Clinic, Fundación Jiménez Díaz, Spain, PMID19318025; 1 case from Centre for Heart Lung Innovation, University of British Columbia, Canada, PMID31345425; and 1case from Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, China, PMID30526649). One index case fulfil FH diagnosis criteria established by the Societa Italiana per lo Studio della Arteriosclerosi, CEINGE-Biotecnologie Avanzate, Napoli, Italy, PMID21865347. Two index cases fulfil Japanese FH guidelines, from Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, PMID31491741. There are three other variants in the same codon: LDLR: NM_000527: c.973T>C (p.Cys325Arg), LDLR: NM_000527: c.974G>C (p.Cys325Ser), LDLR: NM_000527: c.974G>T (p.Cys325Phe), which are classified as Uncertain significance by these guidelines. Therefore PM5 is not met.
LDLR-LOVD, British Heart Foundation	RCV000238286	SCV000295121	likely pathogenic	Hypercholesterolemia, familial, 1	2016-03-25	criteria provided, single submitter	literature only
Fundacion Hipercolesterolemia Familiar	RCV000238286	SCV000607539	likely pathogenic	Hypercholesterolemia, familial, 1	2016-03-01	criteria provided, single submitter	research
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000588581	SCV000697256	likely pathogenic	Familial hypercholesterolemia	2024-06-19	criteria provided, single submitter	clinical testing	Variant summary: LDLR c.974G>A (p.Cys325Tyr) results in a non-conservative amino acid change located in the EGF-like domain (IPR000742) of the encoded protein sequence. Cys325 is a highly conserved residue located in the EGF-like calcium-binding domain of the LDL receptor, HGMD lists >50 Cys missense mutations reported in the literature as associated with hypercholesterolaemia, and five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251090 control chromosomes. .974G>A has been reported in the literature in individuals affected with Familial Hypercholesterolemia and coronary artery disease (e.g. Romano_2011, Alonso_2009, Rubba_2017, Cao_2018, Trinder_2019, Hori_2019, Di Taranto_2020, Wang_2020, Bertolini_2020, Doi_2021), including at least two homozygotes. One homozygous patient had this variant in cis with c.(940+1_941-1)_(2311+1_2312-1)dup (Gly314_Gln770dup, exon 7-15 duplication, described as pathogenic) (Di Taranto_2020). These data indicate that the variant may be associated with disease. Two functional studies report experimental evidence evaluating an impact of the variant on protein function and have shown it to have significantly decreased LDLR residual activity in EBV-transformed B-lymphocytes and stimulated T-lymphocytes (Romano_2011, Bertolini_2020). The following publications have been ascertained in the context of this evaluation (PMID: 19318025, 21865347, 29874871, 31947532, 31491741, 32977124, 33418990, 33079599, 34297352, 30526649, 34496902, 33533259, 28353356, 31345425, 32759540, 35929461). ClinVar contains an entry for this variant (Variation ID: 251580). Based on the evidence outlined above, the variant was classified as likely pathogenic.
Brunham Lab, Centre for Heart and Lung Innovation, University of British Columbia	RCV000238286	SCV001432620	pathogenic	Hypercholesterolemia, familial, 1	2019-06-05	criteria provided, single submitter	research
Labcorp Genetics (formerly Invitae), Labcorp	RCV000588581	SCV001544522	pathogenic	Familial hypercholesterolemia	2023-10-23	criteria provided, single submitter	clinical testing	This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 325 of the LDLR protein (p.Cys325Tyr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with clinical features of familial hypercholesterolemia (PMID: 21865347, 30526649, 32759540, 32977124, 33418990; Invitae). ClinVar contains an entry for this variant (Variation ID: 251580). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LDLR protein function. This variant affects a cysteine residue located within an LDLRA or epidermal-growth-factor (EGF)-like domains of the LDLR protein. Cysteine residues in these domains have been shown to be involved in the formation of disulfide bridges, which are critical for protein structure and stability (PMID: 7548065, 7603991, 7979249). In addition, missense substitutions within the LDLRA and EGF-like domains affecting cysteine residues are overrepresented among patients with hypercholesterolemia (PMID: 18325082). This variant disrupts the p.Cys325 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 26802169). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Laboratory of molecular diagnosis of dyslipidemias, Università egli studi di Napoli Federico II	RCV000238286	SCV001653614	likely pathogenic	Hypercholesterolemia, familial, 1	2021-05-24	criteria provided, single submitter	clinical testing	Reduced activity, in stimulated T-lymphocytes and EBV-transformed B-lymphocytes.
GeneDx	RCV002256181	SCV002526591	likely pathogenic	not provided	2024-09-27	criteria provided, single submitter	clinical testing	Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies suggest a damaging effect with reduced LDLR activity compared to wild type (PMID: 21865347, 35474963); Also known as p.(C304Y); This variant is associated with the following publications: (PMID: 30526649, 19318025, 31491741, 21865347, 33079599, 29874871, 34297352, 34496902, 35474963, 32759540, 31345425, 33418990, 31947532, 33533259, 2988123, 12459547, 28353356, 32977124, Imran2024[article], 35929461)
Ambry Genetics	RCV002379058	SCV002693914	pathogenic	Cardiovascular phenotype	2022-01-24	criteria provided, single submitter	clinical testing	The p.C325Y pathogenic mutation (also known as c.974G>A), located in coding exon 7 of the LDLR gene, results from a G to A substitution at nucleotide position 974. The cysteine at codon 325, located in the EGF-like 1 domain, is replaced by tyrosine, an amino acid with highly dissimilar properties. Pathogenic LDLR mutations that result in the substitution or generation of cysteine residues within the cysteine-rich LDLR class A repeats and EGF-like domains are common in familial hypercholesterolemia (FH) (Villéger L. Hum Mutat. 2002;20(2):81-7). This particular alteration has been detected in multiple individuals reported to have familial hypercholesterolemia (FH), and in individuals from FH cohorts (Alonso R et al. Clin Biochem. 2009;42:899-903; Romano M et al. J Lipid Res. 2011;52:2095-100; Hori M et al. Atherosclerosis. 2019 10;289:101-108; Wang H et al. J Atheroscler Thromb. 2020 Dec;27(12):1288-1298; Meshkov A et al. Genes (Basel). 2021 01;12(1); Ambry internal data). Internal structural analysis indicates this alteration eliminates a disulfide bond critical for the structural integrity of the EGF-like 1 domain (Ambry internal data). In a study of patient-derived lymphocytes, this alteration was reported to reduce LDLR activity to approximately 50% of wildtype (Romano M et al. J Lipid Res. 2011;52:2095-100). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Fulgent Genetics, Fulgent Genetics	RCV000238286	SCV002806168	pathogenic	Hypercholesterolemia, familial, 1	2022-04-20	criteria provided, single submitter	clinical testing